Circulating hsa-miR-323b-3p in Huntington's Disease: A Pilot Study

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Huntington's disease (HD) is a neurodegenerative disorder with limited biomarkers.
• Gene therapy for HD necessitates accessible peripheral biomarkers for patient management.

Purpose of the Study:

• To investigate plasma microRNA profiles as potential biomarkers for Huntington's disease.
• To identify specific microRNAs that can serve as peripheral reporters for HD management and progression.

Main Methods:

• Exploratory microarray analysis of plasma non-coding RNA in HD patients and controls.
• Validation of candidate microRNAs using digital droplet PCR (ddPCR) in an independent cohort.
• Bioinformatic analysis of microRNA targetomes and the huntingtin (HTT) interactome.

Main Results:

• Downregulation of hsa-miR-98 and upregulation of hsa-miR-323b-3p were initially observed in HD patients.
• Validation confirmed significant upregulation of hsa-miR-323b-3p in plasma of HD and premanifest HD patients compared to controls.
• Bioinformatic analysis revealed significant overconnectivity between hsa-miR-323b-3p targetome and the HTT interactome, suggesting biological plausibility.

Conclusions:

• Plasma hsa-miR-323b-3p is a potential minimally invasive biomarker for Huntington's disease.
• This microRNA may aid in characterizing disease progression and monitoring therapeutic interventions.
• Further longitudinal studies with larger sample sizes are warranted to validate these findings.